etrasimod
Trade name: Velsipity
Small moleculeapproved
Approved
Oct 12, 2023
Clinical trial activity
20 trials · 7 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
13
Phase 3
7
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03945188)
Timeline
Indications
Approved for
Mechanism of action
S1PR1 agonist
Sphingosine 1-phosphate receptor Edg-6 modulator
Sphingosine 1-phosphate receptor Edg-8 modulator
Sphingosine 1-phosphate receptor Edg-1 modulator
Approval history
- approvedOct 12, 2023
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21- Mol. weight
- 457.49 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3358920 ↗
- ChEMBLCHEMBL3989933 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07243639 | N/A | Oct 1, 2025 | Showa Inan General Hospital |
| NCT07153159 | Phase 1 | Aug 7, 2025 | Pfizer |
| NCT06521762 | Phase 2 | Aug 31, 2024 | Pfizer, Yale University |
| NCT06140290 | Phase 1 | Dec 11, 2023 | Pfizer |
| NCT05956002 | Phase 1 | Sep 4, 2023 | Pfizer |
| NCT05732454 | Phase 2/Phase 3 (Phase 3) | Jan 18, 2023 | Pfizer |
| NCT05287126 | Phase 2 | Jan 15, 2023 | Arena Pharmaceuticals, Pfizer |
| NCT05061446 | Phase 2 | Oct 16, 2021 | Arena Pharmaceuticals |
| NCT05033340 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2021 | Arena Pharmaceuticals, Cairo University |
| NCT04682639 | Phase 2 | Dec 31, 2020 | Arena Pharmaceuticals |
| NCT04706793 | Phase 3 | Dec 25, 2020 | Arena Pharmaceuticals |
| NCT04607837 | Phase 2 | Nov 10, 2020 | Arena Pharmaceuticals |
| NCT04556734 | Phase 2 | Aug 31, 2020 | Arena Pharmaceuticals |
| NCT03996369 | Phase 3 | Jun 30, 2020 | Arena Pharmaceuticals |
| NCT04173273 | Phase 2 | Dec 31, 2019 | Arena Pharmaceuticals |
| NCT04162769 | Phase 2 | Oct 24, 2019 | Arena Pharmaceuticals |
| NCT03950232 | Phase 3 | Sep 30, 2019 | Arena Pharmaceuticals |
| NCT04176588 | Phase 3 | Sep 10, 2019 | Everstar Therapeutics Limited, People's Liberation Army of China |
| NCT03945188 | Phase 3 | Jun 30, 2019 | Arena Pharmaceuticals |
| NCT06025227 | N/A | — | Pfizer |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arena Pharmaceuticals | For profit | 12 | 12 | 2 | 2019 |
| Pfizer | For profit | 7 | 5 | 4 | 2023 |
| Cairo University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Everstar Therapeutics Limited | For profit | 1 | 1 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2019 |
| Showa Inan General Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2024 |
7 organizations
Page 1 / 1